Re-examining the role of prostate-specific antigen density in predicting outcome for clinically localized prostate cancer

Urology

Volumn 50, Issue 1, 1997, Pages 73-78

  Ingenito, Anthony C ^b   Ennis, Ronald D ^a   Hsu, I Chow ^b   Begg, Melissa D ^b   Benson, Mitchell C ^b   Schiff, Peter B ^b  

^a Columbia University ^*  (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ARTICLE; CANCER RADIOTHERAPY; CANCER SURVIVAL; DIAGNOSTIC VALUE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; TREATMENT OUTCOME;

ADENOCARCINOMA; DISEASE-FREE SURVIVAL; HUMANS; MALE; MULTIVARIATE ANALYSIS; PROGNOSIS; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 0030811940     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(97)00202-1     Document Type: Article

References (33)

1. Chan DW, Bruzek DJ, Oesterling JE, Rock RC, and Walsh PC: Prostate-specific antigen as a marker for prostatic cancer: a monoclonal and a polyclonal immunoassay compared. Clin Chem 33: 1916-1920, 1987.
2. Graves HC, Wehner N, and Stamey TA: Comparison of a polyclonal and monoclonal immunoassay for PSA: need for an international antigen standard. J Urol 144: 1516-1522, 1990.
3. Hortin GL, Bahnson RR, Daft M, Chan KN, Catalona WJ, and Ladenson JH: Differences in values obtained with 2 assays of prostate specific antigen. J Urol 139: 762-765, 1988.
4. Stamey TA, Kabalin JN, McNeal JE, Johnstone IM, Freiha F, Redwine EA, and Yang N: Prostate specific antigen in the diagnosis and treatment of adenocarcinoma of the prostate: II. Radical prostatectomy treated patients. J Urol 141: 1076-1083, 1989.
5. Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, and Redwine E: Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 317: 909-916, 1987.
6. Benson MC, and Olsson CA: Prostate specific antigen and prostate specific antigen density: Roles in patient evaluation and management. Cancer 74: 1667-1673, 1994.
7. Benson MC, Whang IS, Olsson CA, McMahon DJ, and Cooner WH: The use of prostate specific antigen density to enhance the predictive value of intermediate levels of serum prostate specific antigen. J Urol 147: 817-821, 1992.
8. Benson MC, Whang IS, Pantuck A, Ring K, Kaplan SA, Olsson CA, and Cooner WH: Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer. J Urol 147: 815-816, 1992.
9. Bretton PR, Evans WP, Borden JD, and Castellanos RD: The use of prostate specific antigen density to improve the sensitivity of prostate specific antigen in detecting prostate carcinoma. Cancer 74: 2991-2995, 1994.
10. Littrup PJ, Kane RA, Williams CR, Egglin TK, Lee F, Torp-Pedersen S, and Church PA: Determination of prostate volume with transrectal US for cancer screening: part I. Comparisons with prostate-specific antigen assays. Radiology 178: 537-542, 1991.
11. Veneziano S, Pavlica P, Querze R, Nanni G, Lalanne MG, and Vecchi F: Correlation between prostate-specific antigen and prostate volume, evaluated by transrectal ultrasonography: usefulness in diagnosis of prostate cancer. Eur Urol 18: 112-116, 1990.
12. Brawer MK, Aramburu EA, Chen GL, Preston SD, and Ellis WJ: The inability of prostate specific antigen index to enhance the predictive value of prostate specific antigen in the diagnosis of prostatic carcinoma. J Urol 150: 369-373, 1993.
13. Nishiya M, Miller GJ, Lookner DH, and Crawford ED: Prostate specific antigen density in patients with histologically proven prostate carcinoma. Cancer 74: 3002-3009, 1994.
14. Seaman EK, Wang IS, Cooner W, Olsson CA, and Benson MC: Predictive value of prostate-specific antigen density for the presence of micrometastatic carcinoma of the prostate. Urology 43: 645-648, 1994.
15. Zentner PG, Pao LK, Benson MC, McMahon DJ, and Schiff PB: Prostate-specific antigen density: a new prognostic indicator for prostate cancer. Int J Radiat Oncol Biol Phys 27: 47-58, 1993.
16. Corn BW, Hanks GE, Lee WR, Bonin SR, Hudes G, and Schultheiss T: Prostate specific antigen density is not an independent predictor of response for prostate cancer treated by conformal radiotherapy.; Urol 153: 1855-1859, 1995.
17. D'Amico AV, and Propert KJ: Prostate cancer volume adds significantly to prostate specific antigen in the prediction of early biochemical failure after external beam radiation therapy. Int J Radiat Oncol Biol Phys 35: 273-279, 1996.
18. Beahrs OH, Henson DR, Hutter RV, and Kennedy BJ: Manual for Staging of Cancer, 4th ed. Philadelphia, JB Lippincott, 1992, pp 181-186.
19. Littrup PJ, Williams CR, Egglin TK, and Kane RA: Determination of prostate volume with transrectal US for cancer screening: part II. Accuracy of in vitro and in vivo techniques. Radiology 179: 49-53, 1991.
20. Kaplan EL, and Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457-481, 1958.
21. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Can Chemo Rep 50: 163-170, 1966.
22. Cox DR, and Oakes D: Analysis of Survival Data. London, Chapman and Hall, 1984.
23. Pollack A, Lankford S, Zagars GK, and Babain RJ: Prostate specific antigen density as a prognostic factor for patients with prostate carcinoma treated with radiotherapy. Cancer 77: 1515-1523, 1996.
24. Partin AW, Carter HB, Chan DW, Epstein JI, Oesterling JE, Rock RC, Weber JP, and Walsh PC: Prostate specific antigen in the staging of localized prostate cancer: influence of tumor differentiation, tumor volume and benign hyperplasia. J Urol 143: 747-752, 1990.
25. Kavadi VS, Zagars GK, and Pollack A: Serum prostate-specific antigen after radiation therapy for clinically localized prostate cancer: prognostic implications. Int J Radiat Oncol Biol Phys 30: 279-287, 1994.
26. Pisansky TM, Cha SS, Earle JD, Durr ED, Kozelsky TF, Wieand HS, and Oesterling JE: Prostate-specific antigen as a pretherapy prognostic factor in patients treated with radiation therapy for clinically localized prostate cancer. J Clin Oncol 11: 2158-2166, 1993.
27. Ritter MA, Messing EM, Shanahan TG, Potts S, Chappell RJ, and Kinsella TJ: Prostate-specific antigen as a predictor of radiotherapy response and patterns of failure in localized prostate cancer. J Clin Oncol 10: 1208-1217, 1992.
28. Zagars GN: Prostate specific antigen as an outcome variable for T1 and T2 prostate cancer treated by radiation therapy. J Urol 152: 1786-1791, 1994.
29. Zagars GN, Pollack A, Kavadi VS, and von Eschenbach AC: Prostate-specific antigen and radiation therapy for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 32: 293-306, 1995.
30. Zagars GK, and von Eschenbach AC: Prostate-specific antigen. An important marker for prostate cancer treated by external beam radiation therapy. Cancer 72: 538-548, 1993.
31. Kaplan ID, Cox RS, and Bagshaw MA: Prostate specific antigen after external beam radiotherapy for prostatic cancer: followup. J Urol 149: 519-522, 1993.
32. Lee WR, Hanks GE, Schultheiss TE, Corn BW, and Hunt MA: Localized prostate cancer treated by external-beam radiotherapy alone: serum prostate-specific antigen-driven outcome analysis. J Clin Oncol 13: 464-469, 1995.
33. Zietman AL, Coen JJ, Dallow KC, and Shipley WU: The treatment of prostate cancer by conventional radiation therapy: an analysis of long term outcome. Int J Radial Oncol Biol Phys 32: 287-292, 1995.